One of the most promising PIM inhibitors (PIMi) was SGI-1776, a compound with activity against PIM1, PIM2 and PIM3 at nanomolar concentrations [13], [14], [15], which induced apoptosis at micromolar doses in chronic lymphocytic leukemia [17], mantle cell lymphoma [18], and acute myeloid leukemia [19]. Here, PIM2 is linked to mantle cell lymphoma.